Delayed contamination detection wastes material and capacity. This is made worse in integrated/continuous processing.
Identification of rapid methods (results in 8 hours or less) and integration of those methods into quality systems.
Waste of product and downtime due to contamination is reduced
Reduction of time to results from 5 days to 8 hours or less
Saves 4 days plant capacity after each contamination
By implementing the rapid microbial testing with a two-tiered control strategy identified in this project, an organization could reduce the risk of wasted raw materials and plant time due to undetected contamination by up to 80%, enabling real-time process monitoring and faster decision-making for continuous bioprocessing.
The primary deliverable of this project will be a peer-reviewed publication that explores rapid micro technologies and their potential to enhance efficiency, scalability, and innovation within the biopharmaceutical industry.
Ramos, I., Najera, M., & Schaefer, G. (2024). Integration of rapid bioburden testing into production quality management systems and process control. Biotechnology Progress, 40(3). https://doi.org/10.1002/btpr.3431
Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Eli Lilly and Company
AstraZeneca
Bristol-Myers Squibb
CSL Behring, LLC
Catalent Pharma Solutions, LLC
Cytiva
EMD Millipore Corporation
Genentech, Inc.
GlaxoSmithKline, LLC
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
NIIMBL
Pfizer, Inc.
Resilience US
Sanofi
Sartorius Stedim